UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
The Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): March 7, 2006
(March 1, 2006)
CYTOKINETICS, INCORPORATED
(Exact name of registrant as specified in its charter)
| |
|
|
|
|
| |
|
|
|
|
| DELAWARE |
|
000-50633 |
|
94-3291317 |
(State or other jurisdiction
of incorporation)
|
|
(Commission File Number)
|
|
(IRS Employer
Identification No.) |
280 East Grand Avenue
South San Francisco, California 94080
(Address of principal executive offices, including zip code)
650-624-3000
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
| o |
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| |
| o |
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| |
| o |
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
TABLE OF CONTENTS
Item 1.01. Entry into a Material Definitive Agreement.
On March 1, 2006,
the Compensation Committee of the Board of Directors of
Cytokinetics, Incorporated (the “Company”)
voted to approve the bonuses awarded to the Company’s named executive officers (as defined in Item
402(a)(3) of Regulation S-K promulgated by the Securities and
Exchange Commission) with respect to
the officers’ and the Company’s performance for the fiscal year ended December 31, 2005. The
bonus payments were based on meeting specified targets with respect
to the Company’s clinical
development programs for its product candidates, advancement of its research programs for potential
product candidates and its cash position. The following bonuses were awarded for fiscal year 2005:
| |
|
|
|
|
| Name and Title |
|
Bonus |
|
James H. Sabry |
|
|
|
|
Chief Executive Officer |
|
$ |
132,800 |
|
Robert I. Blum |
|
|
|
|
President |
|
$ |
99,663 |
|
Andrew A. Wolff |
|
|
|
|
Senior Vice President, Clinical Research and Development and Chief Medical Officer |
|
$ |
66,000 |
|
Sharon A. Surrey-Barbari |
|
|
|
|
Senior Vice President, Finance and Chief Financial Officer |
|
$ |
65,875 |
|
David J. Morgans, Jr. |
|
|
|
|
Senior Vice President, Pre-Clinical Research and Development |
|
$ |
60,563 |
|
On March 1, 2006,
the Compensation Committee of the Board of Directors also approved fiscal
year 2006 base salaries for the named executive officers. The Compensation Committee of the Board of
Directors annually evaluates the performance and determines the compensation of the Company’s
officers based on the Compensation Committee’s assessment of
each officer’s individual performance,
corporate performance, and a survey of representative peer group
biopharmaceutical companies at similar stages of development based in
the United States. The 2006 base salaries for the
named executive officers are listed in Exhibit 10.60 and are incorporated herein by reference.
These salaries may be changed at any time at the Compensation
Committee’s discretion. Each of
the named executive officers is employed “at will.”
Item 9.01. Financial Statements and Exhibits.
(c) Exhibits.
| |
|
|
| Exhibit No. |
|
Description |
10.60
|
|
2006 Base Salaries for Named Executive Officers. |
2